SELLAS Life Sciences Group, Inc. (SLS)
11.74
+0.41
(+3.62%)
USD |
NASDAQ |
Oct 02, 16:00
11.75
+0.01
(+0.09%)
After-Hours: 20:00
SELLAS Life Sciences Group Enterprise Value : 2.233B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 2.233B |
| October 01, 2026 | 2.150B |
| September 30, 2026 | 2.348B |
| September 29, 2026 | 2.186B |
| September 28, 2026 | 2.203B |
| September 25, 2026 | 2.207B |
| September 24, 2026 | 2.281B |
| September 23, 2026 | 2.188B |
| September 22, 2026 | 2.289B |
| September 21, 2026 | 2.158B |
| September 18, 2026 | 2.182B |
| September 17, 2026 | 2.190B |
| September 16, 2026 | 2.217B |
| September 15, 2026 | 2.142B |
| September 14, 2026 | 2.230B |
| September 11, 2026 | 2.193B |
| September 10, 2026 | 2.586B |
| September 09, 2026 | 2.679B |
| September 08, 2026 | 2.681B |
| September 04, 2026 | 2.661B |
| September 03, 2026 | 2.629B |
| September 02, 2026 | 2.721B |
| September 01, 2026 | 2.532B |
| August 31, 2026 | 2.556B |
| August 28, 2026 | 2.530B |
| Date | Value |
|---|---|
| August 27, 2026 | 2.933B |
| August 26, 2026 | 2.635B |
| August 25, 2026 | 2.707B |
| August 24, 2026 | 2.755B |
| August 21, 2026 | 2.984B |
| August 20, 2026 | 2.568B |
| August 19, 2026 | 2.659B |
| August 18, 2026 | 2.507B |
| August 17, 2026 | 2.487B |
| August 14, 2026 | 2.443B |
| August 13, 2026 | 2.358B |
| August 12, 2026 | 2.239B |
| August 11, 2026 | 2.093B |
| August 10, 2026 | 2.091B |
| August 07, 2026 | 2.287B |
| August 06, 2026 | 2.225B |
| August 05, 2026 | 2.257B |
| August 04, 2026 | 2.247B |
| August 03, 2026 | 2.128B |
| July 31, 2026 | 1.884B |
| July 30, 2026 | 1.940B |
| July 29, 2026 | 1.902B |
| July 28, 2026 | 1.900B |
| July 27, 2026 | 2.050B |
| July 24, 2026 | 2.148B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 528.72B |
| Capricor Therapeutics, Inc. | 373.19M |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Incyte Corp. | 18.68B |
| Insmed, Inc. | 23.84B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.605M |
| Total Expenses (Quarterly) | 9.605M |
| EPS Diluted (Quarterly) | -0.0508 |
| Earnings Yield | -1.81% |
| Normalized Earnings Yield | -1.808 |